BiotechTube
Clarix Imaging

Clarix Imaging

San Francisco, United States· Est.
clariximaging.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $3.2M

Overview

Clarix Imaging is a private, commercial-stage medical device company founded in 2017 and based in San Francisco. It has developed and received FDA clearance for the VSI-360™, a novel imaging system that generates true 3D reconstructions of surgical specimens to help surgeons assess margin status during breast cancer lumpectomy procedures. The technology, born from NIH-funded research at the University of Chicago, aims to reduce the need for repeat surgeries by providing intraoperative clarity. The company is currently in early revenue generation, deploying its system to hospital partners and conducting prospective clinical trials.

Oncology

Technology Platform

True 3D volumetric specimen imaging (VSI) platform for intraoperative visualization of surgical margins, based on rotational imaging and 3D reconstruction.

Funding History

1
Total raised:$3.2M
Seed$3.2M

Opportunities

The primary opportunity is to significantly reduce the 20-30% re-excision rate in breast lumpectomy procedures, offering substantial clinical and economic value to healthcare systems.
The underlying 3D volumetric imaging platform could be expanded to other surgical oncology areas where margin assessment is critical, such as melanoma or head and neck cancers.
Successful clinical data generation could also position the company as an attractive acquisition target for larger medical device firms.

Risk Factors

Key risks include the challenge of driving adoption in cost-sensitive hospital systems, which requires proving a rapid return on investment.
The company faces competition from incremental improvements to existing 2D/tomosynthesis systems and must successfully execute the scaling of manufacturing, sales, and support operations.
There is also concentration risk, as the company's success is currently tied to a single product for a single application.

Competitive Landscape

Clarix competes with traditional 2D specimen radiography systems and emerging intraoperative tomosynthesis devices, which offer pseudo-3D images. Other competitors include frozen section pathology analysis and newer technologies like radiofrequency spectroscopy or mass spectrometry. Clarix's differentiation is its claim of providing a true, isotropic 3D volumetric view, which may offer superior margin visualization compared to existing alternatives.

More companies in Diagnostics & Precision Medicine →More companies in United States →